<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063125</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00140348</org_study_id>
    <nct_id>NCT03063125</nct_id>
  </id_info>
  <brief_title>Hypogonadism in Bladder Cancer</brief_title>
  <official_title>Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the relationship between testosterone level changes
      around the time of radical cystectomy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 31, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of hypogonadism</measure>
    <time_frame>90 days post-RC surgery</time_frame>
    <description>The prevalence rates will be calculated as the proportion of subjects with hypogonadism.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of hypogonadism</measure>
    <time_frame>30 days post-RC surgery</time_frame>
    <description>The prevalence rates will be calculated as the proportion of subjects with hypogonadism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of hypogonadism</measure>
    <time_frame>Immediately post-operatively RC surgery</time_frame>
    <description>The prevalence rates will be calculated as the proportion of subjects with hypogonadism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of hypogonadism</measure>
    <time_frame>Baseline, prior to RC surgery</time_frame>
    <description>The prevalence rates will be calculated as the proportion of subjects with hypogonadism.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Low Testosterone Levels</condition>
  <arm_group>
    <arm_group_label>Bladder Cancer Patients</arm_group_label>
    <description>Patients with bladder cancer scheduled to undergo radical cystectomy (RC).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from patients being treated at the University of Kansas
        Health System.Potiential patients will be recruited from the urology clinic, University of
        Kansas Cancer Center or during inpatient hospitalization.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of bladder cancer

          -  Scheduled to undergo radical cystectomy

        Exclusion Criteria:

          -  Evidence of advanced metastatic disease,

          -  Undergoing cystectomy for non-bladder primary malignancy or bladder cancer type other
             than urothelial cell

          -  History of breast or prostate cancer

          -  Polycythemia, cardiovascular thromboembolism, untreated obstructive sleep apnea,
             uncontrolled heart failure, or acute coronary event in the past six months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Eligible participants are adult men undergoing RC for primary bladder cancer.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Holzbeierlein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radical cystectomy</keyword>
  <keyword>hypogonadism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

